Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Link opens in a new tab
Search content at Maastricht University
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
Current and future biomarkers for pancreatic adenocarcinoma
Sven H. Loosen
,
Ulf P. Neumann
, Christian Trautwein
, Christoph Roderburg
, Tom Luedde
*
*
Corresponding author for this work
Surgery
FHML non-thematic output
Research output
:
Contribution to journal
›
(Systematic) Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current and future biomarkers for pancreatic adenocarcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pancreatic Cancer
100%
Pancreatic Adenocarcinoma
100%
New Biomarkers
100%
Pancreatic Ductal Adenocarcinoma
50%
Predictive Biomarker
50%
Treatment Options
25%
Curative Treatment
25%
Disease Stage
25%
Surgical Resection
25%
Early Detection
25%
Therapeutic Approaches
25%
Mortality Rate
25%
Incidence Rate
25%
Most Common Form
25%
Advanced Disease
25%
Novel Biomarkers
25%
Poor Prognosis
25%
Diagnostic Potential
25%
Carbohydrate Antigen 19-9 (CA19-9)
25%
Diagnostic Marker
25%
5-year Survival
25%
Current Diagnostics
25%
Side Effect Profile
25%
Personalized Treatment
25%
Treatment Decisions
25%
Cancer Types
25%
Advanced Stage
25%
Treatment Choice
25%
U.S. Food
25%
Future Diagnostics
25%
Unfavorable Prognosis
25%
Palliative Chemotherapy
25%
Diagnostic Interventions
25%
Untargeted
25%
Low Performance Status
25%
Restricted Sensitivity
25%
INIS
pancreas
100%
biological markers
100%
adenocarcinomas
100%
cancer
71%
patients
57%
diseases
28%
detection
14%
antigens
14%
specificity
14%
sensitivity
14%
surgery
14%
information
14%
mortality
14%
side effects
14%
reviews
14%
chemotherapy
14%
performance
14%
food and drug administration
14%
carbohydrates
14%
Medicine and Dentistry
Biological Marker
100%
Pancreas Cancer
100%
Pancreas Adenocarcinoma
100%
Diseases
50%
Sensitivity and Specificity
25%
Malignant Neoplasm
25%
Side Effect
25%
Mortality Rate
25%
Survival Rate
25%
CA 19-9 Antigen
25%
Diagnostic Marker
25%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Pancreas Cancer
100%
Pancreas Adenocarcinoma
100%
Diseases
50%
Malignant Neoplasm
25%
Side Effect
25%
Survival Rate
25%
Mortality Rate
25%
Chemotherapy
25%
CA 19-9 Antigen
25%